Palisade Bio surged 14.44% during intraday trading after Maxim raised its price target to $8 from $2 and maintained a Buy rating, citing lower risk. The upgraded target reflects increased confidence in the firm’s prospects, likely driving investor buying.
Comments
No comments yet